Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

BACKGROUND: Drug resistance is a major obstacle to treating cancers because it desensitizes cancer cells to chemotherapy. Recently, attention has been focused on changes in the tumor immune landscape after the acquisition of drug resistance. Programmed death-ligand-1 (PD-L1) is an immune suppressor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haifang, Fu, Chen, Du, Jun, Wang, Hongsheng, He, Rui, Yin, Xiaofeng, Li, Haixia, Li, Xin, Wang, Hongxia, Li, Kui, Zheng, Lei, Liu, Zongcai, Qiu, Yurong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003365/
https://www.ncbi.nlm.nih.gov/pubmed/32024543
http://dx.doi.org/10.1186/s13046-020-1536-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003365/
https://www.ncbi.nlm.nih.gov/pubmed/32024543
http://dx.doi.org/10.1186/s13046-020-1536-x

Ejemplares similares